BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30808702)

  • 1. HIV-1 Escape from Small-Molecule Antagonism of Vif.
    Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
    mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
    Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
    J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.
    Miyagi E; Welbourn S; Sukegawa S; Fabryova H; Kao S; Strebel K
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
    Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
    Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
    Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
    Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
    Letko M; Booiman T; Kootstra N; Simon V; Ooms M
    Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.
    Chesarino NM; Emerman M
    J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
    Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
    Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term passage of Vif-null HIV-1 in CD4
    Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
    Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
    Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
    Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
    Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
    mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
    Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
    Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
    Huang W; Zuo T; Jin H; Liu Z; Yang Z; Yu X; Zhang L; Zhang L
    Mol Divers; 2013 May; 17(2):221-43. PubMed ID: 23378232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis.
    Zhong X; Luo R; Yan G; Ran K; Shan H; Yang J; Liu Y; Yu S; Pu C; Zheng Y; Li R
    Eur J Med Chem; 2021 Nov; 224():113680. PubMed ID: 34245947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
    Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
    J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.